An­nex­on pro­claims Phase 3 win for com­ple­ment in­hibitor in Guil­lain-Bar­ré syn­drome

Last year
R&D

Ex­clu­sive: In­spired by Spin­raza, start­up rais­es $25M for can­cer drug tar­gets cre­at­ed by al­ter­na­tive RNA splic­ing

Last year
Financing
AI

Mer­ck KGaA con­tin­ues AI drug dis­cov­ery deal spree with Bi­olo­jic De­sign 

Last year
Deals
AI

Aus­tralian life sci­ences VC Bran­don Cap­i­tal rais­es $180M for sixth fund

Last year
Financing
Startups

Il­lu­mi­na board agrees to spin off Grail rather than sell the can­cer di­ag­nos­tics firm

Last year
Deals
Diagnostics

Sanofi touts Phase 3 Sar­clisa da­ta in mul­ti­ple myelo­ma as it plays catch-up with J&J’s Darza­lex

Last year
R&D
Pharma

How Farm­boxRx us­es food de­liv­er­ies to en­cour­age pa­tients to get pre­ven­tive care

Last year
Startups
Health Tech

At AS­CO: big read­outs, rev­enue ques­tions, and the ups and downs of AD­Cs

Last year
R&D
Pharma

Fau­ci push­es back on pan­dem­ic crit­i­cisms be­fore di­vid­ed House pan­el

Last year
Pharma
FDA+

Agios plans tha­lassemia fil­ing in US af­ter un­veil­ing da­ta in trans­fu­sion-de­pen­dent pa­tients

Last year
Pharma
FDA+

Struc­ture's oral GLP-1 pro­duces com­pa­ra­ble weight loss to Lil­ly's oral can­di­date

Last year
R&D

Af­ter Phase 3 win, Ar­row­head­'s RNAi chas­es Io­n­is to mar­ket en­try in rare ge­net­ic dis­or­der

Last year
R&D

Take­da out­lines mid-stage nar­colep­sy da­ta that prompt­ed 'rapid' move in­to Phase 3

Last year
R&D

Cari­bou says par­tial HLA match­ing will im­prove dura­bil­i­ty of re­sponse to cell ther­a­py 

Last year
R&D

Delaware court lets Zan­tac law­suits go ahead, wip­ing $8B+ from GSK mar­ket cap

Last year
Pharma
Law

Rap­port Ther­a­peu­tics sets out for $122M Nas­daq de­but as IPO back­log seeks fresh air

Last year
Financing
Startups

Eli Lil­ly li­cens­es pre­clin­i­cal an­ti­sense pro­gram de­signed to treat ALS, de­men­tia

Last year
Deals

Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al

Last year
R&D
Pharma

A small group of melanoma pa­tients may need far less im­munother­a­py with surgery, study sug­gests  

Last year
R&D

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

Last year
R&D
China

Dai­ichi Sankyo, As­traZeneca say En­her­tu works bet­ter than chemo in cer­tain breast can­cer pa­tients

Last year
R&D

As­traZeneca, J&J share new da­ta in bids to ex­pand reach of lung can­cer drugs

Last year
R&D

GSK plots Blenrep’s re­turn with more da­ta on its ADC for mul­ti­ple myelo­ma

Last year
R&D
Pharma

In­tel­lia plots Phase 3 study and a 2026 FDA sub­mis­sion af­ter CRISPR ther­a­py cuts swelling at­tacks by 98%

Last year
R&D
Cell/Gene Tx
First page Previous page 148149150151152153154 Next page Last page
A service from the Financial Times